Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial

被引：0
|
作者：
Ferguson, G. T. [1 ]
Rabe, K. F. [2 ,3 ,4 ]
Martinez, F. J.
Wang, C. [5 ]
Singh, D. [6 ,7 ]
Wedzicha, J. [8 ]
Trivedi, R. [9 ]
Rose, E. [9 ]
Ballal, S. [9 ]
McLaren, J. [9 ]
Darken, P. [9 ]
Aurivillius, M. [9 ]
Reisner, C. [9 ]
Dorinsky, P. [9 ]
机构：
[1] Pulm Res Inst Southeast Michigan, Farmington Hills, MI USA
[2] Lungenclin Grosshansdorf GmbH, Grosshansdorf, Germany
[3] Zentrum Pneumol & Thoraxchirurg, Grosshansdorf, Germany
[4] Deutsch Zentrum Lungenforsch DZL, Airway Res Ctr North Arcn, Neuherberg, Germany
[5] China Japan Friendship Hosp, Beijing Key Lab Resp & Pulm Circulat Disorders, Natl Clin Res Ctr Resp Dis, Beijing, Peoples R China
[6] Med Evaluat Unit Ltd, Manchester, Lancs, England
[7] Univ Manchester, Manchester, Lancs, England
[8] Imperial Coll London, Natl Herz & Lungeninst, London, England
[9] AstraZeneca, Cambridge, England
来源：
PNEUMOLOGIE | 2021年 / 75卷
关键词：
D O I：
10.1055/s-0041-1723287
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
P634
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [1] Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial
    Ferguson, Gary T.
    Rabe, Klaus F.
    Martinez, Fernando J.
    Wang, Chen
    Singh, Dave
    Wedzicha, Jadwiga A.
    Trivedi, Roopa
    St Rose, Earl
    Ballal, Shaila
    Mclaren, Julie
    Darken, Patrick
    Aurivillius, Magnus
    Reisner, Colin
    Dorinsky, Paul
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [2] COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels
    Martinez, Fernando J.
    Rabe, Klaus F.
    Ferguson, Gary T.
    Wang, Chen
    Singh, Dave
    Wedzicha, Jadwiga A.
    Trivedi, Roopa
    St Rose, Earl
    Ballal, Shaila
    Mclaren, Julie
    Darken, Patrick
    Aurivillius, Magnus
    Reisner, Colin
    Dorinsky, Paul
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [3] Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis
    Rabe, Klaus F.
    Martinez, Fernando J.
    Ferguson, Gary T.
    Wang, Chen
    Singh, Dave
    Wedzicha, Jadwiga A.
    Trivedi, Roopa
    St Rose, Earl
    Ballal, Shaila
    Mclaren, Julie
    Darken, Patrick
    Aurivillius, Magnus
    Reisner, Colin
    Dorinsky, Paul
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [4] Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis
    Rabe, K. F.
    Martinez, F. J.
    Ferguson, G. T.
    Wang, C.
    Singh, D.
    Wedzicha, J.
    Trivedi, R.
    Rose, E.
    Ballal, S.
    McLaren, J.
    Darken, P.
    Aurivillius, M.
    Reisner, C.
    Dorinsky, P.
    PNEUMOLOGIE, 2021, 75 : S12 - S12
  • [5] Single-Inhaler Triple Combination Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) at Two Corticosteroid Dose Levels in COPD: ETHOS Trial
    Rabe, K. F.
    Martinez, F. J.
    Ferguson, G. T.
    Wang, C.
    Singh, D.
    Wedzicha, J. A.
    Trivedi, R.
    St Rose, E.
    Ballal, S.
    McLaren, J.
    Darken, P.
    Aurivillius, M.
    Reisner, C.
    Dorinsky, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [6] COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS
    Rabe, Klaus F.
    Martinez, Fernando J.
    Ferguson, Gary T.
    Singh, Dave
    Wedzicha, Jadwiga A.
    Jenkins, Martin
    Aurivillius, Magnus
    Reisner, Colin
    Dorinsky, Paul
    INTERNIST, 2021, 62 (SUPPL 2): : 181 - 181
  • [7] COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS
    Rabe, K. F.
    Martinez, F. J.
    Ferguson, G. T.
    Singh, D.
    Wedzicha, J.
    Jenkins, M.
    Aurivillius, M.
    Reisner, C.
    Dorinsky, P.
    PNEUMOLOGIE, 2021, 75 : S12 - S13
  • [8] Analysis of exacerbation rates by time interval post-randomization in the KRONOS Phase III study of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI)
    Rabe, Klaus F.
    Fabbri, Leonardo M.
    Martinez, Fernando J.
    Ferguson, Gary T.
    Bourne, Eric
    Ballal, Sheila
    Darken, Patrick
    Deangelis, Kiernan
    Aurivillius, Magnus
    Reisner, Colin
    Dorinsky, Paul
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [9] Benefits of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) on Symptoms and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease (COPD) in the ETHOS Trial
    Martinez, F. J.
    Rabe, K. F.
    Ferguson, G. T.
    Wedzicha, J. A.
    Trivedi, R.
    St Rose, E.
    Ballal, S.
    Darken, P.
    Aurivillius, M.
    Dorinsky, P.
    Reisner, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [10] Relative bioavailability of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) administered with and without a spacer in healthy adults
    Dorinsky, Paul
    Depetrillo, Paolo
    Deangelis, Kiernan
    Trivedi, Roopa
    Mo, Mindy
    Ballal, Shaila
    Gillen, Michael
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
12345